The latest DDW Sitting Down With podcast features Anders Mälarstig Director of Human Genetics, Pfizer.

Mälarstig is currently responsible for developing and applying strategies for new drug targets and precision medicine. He has extensive experience working in international academic consortia and public–private partnerships such as the SCALLOP consortium. In this podcast he outlines the role of pQTLs in the drug discovery process and the growing importance of proteogenomics.

Listen to this podcast to hear Mälarstig discuss proteogenomics, an emerging approach that aims to advance basic, translational and clinical research. He will also explain why the drug discovery sector should take an interest in it, what insights it can provide to researchers and the opportunities it is creating for drug discovery companies.